跳至主要内容
临床试验/NCT05609240
NCT05609240招募中2 期

Colo-Pro_2: A Feasibility Randomised Controlled Double Blind Trial to Compare Standard Bolus Dosed Cefuroxime Prophylaxis to Bolus-continuous Infusion Dosed Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery

University of Leeds3 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2023年5月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
180
试验地点
3
主要终点
Recruitment rates

研究概览

简要总结

After a surgical operation patients may have an infection in the operation wound, the bladder, kidneys or lungs. To stop these infections patients are given a dose of antibiotic before their operation. Unfortunately, the amount of antibiotic available to fight infections falls throughout an operation, being removed from the body by the kidneys. Therefore, antibiotic levels may not be high enough to stop infections. A way of maintaining antibiotic levels throughout an operation is to give a single dose of antibiotic and then a constant amount of antibiotic by an infusion from the start to the end of the operation. A small single centre test study was previosuly undertaken into antibiotic dosing during bowel operations. One group of patients had a single dose of antibiotic before their operation. The other group had a single dose plus a constant dose of antibiotic until the end of their operation. The project showed patients were happy to take part and that the study was safe. The study helped us identify the correct amounts of antibiotic needed for the patients given the single dose plus a constant dose of antibiotic. This study was conducted at one hospital only, and wasn't big enough to confirm if one treatment was better than another or if results would be similar in other hospitals.

This study will build on the pilot study in a larger feasibility trial, the Colo-Pro_2 trial. It will be run in three hospitals so can assess if the trial design works at different hospitals. We will see if the results suggest one treatment, single dose of antibiotics before an operation, or single dose plus a constant dose of antibiotics throughout an operation, is better. This study will include up to 180 patients having bowel operations as they have a high risk of infection. All patients will be given the same antibiotic which is called cefuroxime. Cefuroxime is already used to stop infections after surgery. Using the same antibiotic in all patients means it is possible to know if differences in the number of infections are due to how the antibiotic is given. The number of infections that happen up to 30 days after operations will be counted. Staff looking after patients after the operation and those counting the infections will not know, unless necessary, the treatment patients received. This means the results won't be influenced by knowledge of the treatment received.

详细描述

See attached protocol

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

An anaesthetist will provide the intra-operative intervention and will the subsequently not be involved in the patients follow up or outcome assessment. alternatively, a research nurse not involved in participant follow up will provide the intra-operative intervention.

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Undergoing elective colorectal surgery (incision, excision or anastomosis of the large bowel, including anastomosis of small to large bowel)
  • Expected duration of surgery > 2hours
  • Creatinine clearance > 40 ml/min
  • Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens.
  • Patient capable of giving informed consent
  • Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery, urological surgery, gynaecological surgery.

排除标准

  • Unable to consent
  • Pregnancy
  • Expected duration of surgery <2hours
  • Creatinine clearance <40ml/min
  • Individual level microbiological advice for non-cefuroxime based prophylaxis
  • Cephalosporin allergy
  • Penicillin allergy (hypersensitivity reaction only)
  • Coumarin (warfarin and acenocoumarol) treatment
  • Seizure history or epilepsy
  • Concurrent use of probenecid
  • Current participation in a research project aimed at reducing surgical site infections (SSIs)
  • Antibiotics for treatment of a systemic Gram negative infection within 12 hours of initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin. Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic Gram negative antibiotics).
  • A current diagnosis of infection at the time of study entry.
  • STARR procedures (stapled trans anal resection of the rectum)
  • Weight <30kg or >110kg

研究组 & 干预措施

Standard treatment

Active Comparator

Cefuroxime 1.5 grams intravenous Administered in the hour before surgery and then 4 hourly intra-operatively.

干预措施: Cefuroxime (Drug)

Intervention treatment

Active Comparator

Cefuroxime loading dose of 2332mg intravenous Administered in the hour before surgery.

Following the loading dose a renal function based dosing will be given as a continuous intravenous infusion throughout surgery, as below. Continuous infusion will continue for up to 6 hours when it will return to 4 hourly dosing of cefuroxime at 1.5 grams intravenously, if required.

Creatinine clearance (ml/min) and Cefuroxime:Dose per hour (mg/hr) 40-50ml/min=723mg/hr 50-60ml/min=867mg/hr 60-70ml/min=1011mg/hr 70-80ml/min=1155mg/hr >80ml/min=1227mg/hr

干预措施: Cefuroxime (Drug)

结局指标

主要结局

Recruitment rates

时间窗: 24 months

Rate of recruitment

Retention rates

时间窗: 90 days

Rate of retention

次要结局

  • Health Care Associated Infection(30 days)
  • Microbiological evidence of urinary tract infection (UTI)(30 days)
  • Antimicrobial consumption after colorectal surgery(90 days)
  • Re-admission(90 days)
  • Antimicrobially resistant infections (AMR infections):(90 days)
  • Surgical site infection(30 days)
  • Length of hospital stay(90 days)
  • C. difficile infection(90 days)
  • Anastomotic leakage after colorectal surgery(90 days)
  • Mortality(90 days)
  • Cost of healthcare treatment(90 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew Kirby

Associate Clinical Professor

University of Leeds

研究点 (3)

Loading locations...

相似试验

Colo-Pro_2: Bolus-continuous Infusion Cefuroxime... | 临床试验